Highlights

•

Genetic and epigenetic alterations, metabolic reprogramming, and survival mechanisms govern chemoresistance in cancer.

•

Cancer cells evade drug effects through metabolic reprogramming.

•

Resistance mechanisms are countered by tailored medicine and targeted medicines.

•

Combination regimens use a variety of strategies to overcome resistance

•

Novel treatment approaches to overcome resistance are guided by molecular understanding

The 2024 WHO Bacterial Priority Pathogens List (WHO BPPL) is a critical tool for refining global antimicrobial resistance (AMR) strategy, prioritizing 24 bacteria with a focus on Gram-negatives and community threats like Salmonella Typhi. This perspective examines its One Health implications. While the 2024 WHO BPPL effectively guides research and development (R&D), policy, and infection control through vaccines and water, sanitation and hygiene (WASH) programs, its human-centric approach underrepresents critical agricultural and environmental AMR drivers. Surveillance biases towards high-income countries and the inherent challenges of cross-sectoral monitoring—given the distinct niches of pathogens like Enterococcus faecium and Shigella—further limit its scope. We call for integrating zoonotic and environmental metrics, strengthening global surveillance (e.g., Global Antimicrobial Resistance and Use Surveillance System [GLASS]), and accelerating development of novel therapies to advance a more equitable and holistic AMR response.

New research by UCLA Health and UC San Francisco has uncovered why certain brain cells are more resilient than others to the buildup of a toxic protein that is a hallmark of Alzheimer’s disease and related dementias, potentially leading to new targets for therapies or treatments.

National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical Cancer Research.

At the 2026 Society of Thoracic Surgeons (STS) Annual Meeting, investigators will present a late-breaking study focused on surgical aortic valve replacement (SAVR) following prior transcatheter aortic valve replacement (TAVR), a clinical scenario increasingly encountered as TAVR use expands. Results demonstrate that operative mortality for isolated SAVR after TAVR has declined substantially over time, while the newly developed risk model showed excellent accuracy for all patients and surgical procedures.